Search clinical trials for: Furmonertinib 160mg

Total 1480 results

Allist Pharmaceuticals, Inc.

Recruiting

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation (FAVOUR)

NSCLC

China
Allist Pharmaceuticals, Inc.

Withdrawn

Phase Ib Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

NSCLC

China
Guangdong Raynovent Biotech Co., Ltd

Completed

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics

Nonalcoholic Steatohepatitis

China
Fudan University
Allist Pharmaceuticals, Inc.

Recruiting

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Non-Small-Cell Lung Cancer

China
New Cancer Cure-Bio Co.,Ltd.

Recruiting

Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713

Advanced Solid Tumors

Korea, Republic of
Samjin Pharmaceutical Co., Ltd.

Completed

A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

Healthy

Korea, Republic of
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Advanced Liver Cancer

China
Peking Union Medical College

Recruiting

Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trial（iFORCE）

NSCLC | Brain Metastases | Furmonertinib | EGFR-mutation

China
Peking Union Medical College Hospital

Recruiting

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Xention Ltd

Completed

Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103

Atrial Fibrillation

United Kingdom
The Affiliated Hospital of Qingdao University

Completed

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

Healthy Volunteers

China
Linda Van Eldik
National Institute on Aging (NIA); Duke Clinical Research Institute

Completed

MW151-101: First-in-human Study of MW151

Drug Toxicity

United States
South China Center For Innovative Pharmaceuticals
Xiangya Hospital of Central South University

Completed

Safety, Tolerability and Pharmacokinetics of AD16 Tablets in Adult Healthy Subjects After Single Administration (AD16)

Alzheimer's Disease

China
Sun Yat-sen University

Recruiting

A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

Oligoprogressive | Non-small Cell Lung Cancer

China
Allist Pharmaceuticals, Inc.

Not yet recruiting

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (FORWARD)

Non-small Cell Lung Carcinoma
Stealth BioTherapeutics Inc.

Completed

A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)

Healthy

United States
Jiangsu Province Nanjing Brain Hospital

Recruiting

A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

NSCLC

China
West China Hospital

Recruiting

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

Esophageal Squamous Cell Carcinoma

China
West China Hospital

Recruiting

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas

Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of SYHA1402 in Healthy Subjects

Diabetic Peripheral Neuropathy
BeBetter Med Inc

Completed

Study of Orally Administered BEBT-503 in Healthy Subjects

Healthy Subjects

Australia
Tongji University

Recruiting

Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma (ATHEM)

NSCLC | EGF-R Positive Non-Small Cell Lung Cancer

China
Sun Yat-sen University

Not yet recruiting

Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | RC48 | Disitamab Vedotin

China
National Institute of Neurological Disorders and...

Active, not recruiting

Tolebrutinib, a Brain-penetrant Bruton s Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

Multiple Sclerosis

United States
GlaxoSmithKline

Completed

A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.

Hepatitis C

United States
Boryung Pharmaceutical Co., Ltd

Completed

A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan

Chronic Kidney Disease

Korea, Republic of
Shire

Terminated

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Schizophrenia

United States
Shanghai Zhongshan Hospital
Ningbo No. 1 Hospital; Shanghai Minhang Central Hospital; Xuhui Central Hospital... and other collaborators

Not yet recruiting

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Non-Small Cell Lung Cancer
Genfit
Naturalpha; SGS Aster S.A.S.

Completed

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Cardiovascular Diseases | Metabolic Diseases | Diabetes Mellitus, Type 2 | Type 2 Diabetes | Dyslipidemia | Obese

France
Corcept Therapeutics

Completed

CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Healthy

United Kingdom
Guangzhou Yipinhong Pharmaceutical CO.,LTD

Completed

The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers

Chronic Hepatitis B

China
Dong-A ST Co., Ltd.

Active, not recruiting

Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults

Healthy

Korea, Republic of
Chengdu Zenitar Biomedical Technology Co., Ltd

Not yet recruiting

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

Myeloproliferative Neoplasm (MPN) | Myelofibrosis，MF
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Safety of Flunotinib Maleate Tablets for the Treatment of Patients With Myeloproliferative

Myeloproliferative Neoplasm (MPN) | Myelofibrosis，MF

China
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom
LG Life Sciences

Completed

Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients

Hypertension

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet

Gastritis

Korea, Republic of
CSPC Ouyi Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects

Healthy Participants

China
Zambon SpA

Withdrawn

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

Parkinson Disease | Dyskinesia, Drug-Induced
Galera Therapeutics, Inc.

Completed

A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

Healthy

Australia
Shaheer A. Khan
AstraZeneca; Melanoma Research Alliance

Completed

Intermittent Selumetinib for Uveal Melanoma

Uveal Melanoma

United States
Damanhour University

Recruiting

Fenofibrate Role in Breast Cancer Patients

Breast Cancer

Egypt
Phloronol Inc.
Worldwide Clinical Trials

Completed

Phase I Study of PH100 (Ecklonia Cava Phlorotannins)

Safety Issues

United States
GlaxoSmithKline

Withdrawn

GSK2190915 Pediatric Study

Asthma
University of Patras

Completed

High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Platelet Reactivity

Greece
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia Patients on Hemodialysis

Japan
Sun Yat-sen University
GeneCast Biotechnology Co., Ltd.; Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA (FOCUS-C)

Non-small Cell Lung Cancer

China
Samsung Medical Center
Dong-A Pharmaceutical Co., Ltd.

Unknown

Zydena on Cognitive Function of Alzheimer's Disease Patients

Alzheimer's Disease

Korea, Republic of
Inmagene LLC

Recruiting

Study to Evaluate IMG-004 in Healthy Participants

Healthy Participants

United States
Shandong New Time Pharmaceutical Co., LTD

Completed

Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg

Bioequivalence

China

3

Subscribe